All In MedTech

Device Trial Radar · NCT02970799

Tear Production by Nasal Neurostimulation Compared to Active Control

Randomized, Controlled, Crossover Study Comparing Tear Production by Nasal Neurostimulation Versus Active Control

Last checked: Nov 19, 2026Latest source record: Oct 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

27

Actual

Start

Aug 31, 2016

Primary completion

Oct 31, 2016

Study completion Oct 31, 2016

Sponsor

Lead sponsor
Oculeve, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Nov 22, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This crossover design study evaluates the effectiveness of the Oculeve Intranasal Neurostimulator comparing the effect of intranasal (active) versus extranasal (control) stimulation on tear production as measured by the Jones Schirmer test in participants with dry eye disease.

Conditions

  • Dry Eye
  • Dry Eye Syndromes
  • Keratoconjunctivitis Sicca

Interventions

  • Intranasal NeurostimulatorDevice

    The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acute Tear Production by Jones Schirmer TestTime frame: Day 1

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.